Streetbeat News

Products Services

SILO

Silo Pharma's SPU-21 peptide has shown promising results against Rheumatoid Arthritis in a human tissue study. The study assessed the efficiency, optimization, and binding affinity of SPU-21.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 12:13 pm

MTEK

Maris-Tech Ltd. (NASDAQ:MTEK) has announced plans to expand its commercial activity in the U.S. defense market. The company has appointed industry veteran Adam Emanuel to its advisory board and will partner with Altagrove LLC to promote its AI-accelerated video solutions for integration on unmanned platforms. The company's products are meeting and exceeding the requirements of North American manufacturers and defense contractors.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 12:12 pm

ALDX

Aldeyra Therapeutics has been informed by the FDA that its drug, Reproxalap, for signs and symptoms of dry eye disease, lacks sufficient data to support its clinical relevance. The FDA has suggested that Aldeyra conduct an additional clinical trial to satisfy efficacy requirements. This could delay the approval of the NDA for Reproxalap beyond the target action date of November 23, 2023.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 12:11 pm

MIR

Mirion Technologies (NYSE:MIR) has announced its contribution to NASA's Psyche mission, providing a high-purity germanium (HPGe) gamma-ray detection component. The detector will be used to explore the asteroid Psyche, believed to be composed primarily of metallic iron and nickel. The gamma-ray detector will enable precise measurements of gamma radiation emanating from the asteroid, contributing to the scientific objectives of the mission. Mirion's HPGe detectors also have significant applications on Earth, including in nuclear physics, environmental monitoring, and research applications.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 12:11 pm

SGEN

Seagen Inc. (NASDAQ:SGEN) will present detailed results from two pivotal Phase 3 studies at the ESMO Congress 2023. The studies focus on PADCEV (EV-302) for bladder cancer and TIVDAK (innovaTV 301) for cervical cancer. Both studies met their primary endpoints of overall survival and progression-free survival. The results will be used for global submissions and as confirmatory trials for U.S. accelerated approval. Seagen is also sharing early clinical data from a Phase 1 study of SGN-B7H4V, a wholly owned vedotin ADC directed to B7-H4.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 12:08 pm

BB

BlackBerry has announced a new Generative AI powered cybersecurity assistant, which will initially be made available to a select group of customers.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 12:07 pm

AAPL

GS

Apple Inc.'s shares fell in Monday's premarket due to two concerning reports. One report indicated slower sales for the iPhone 15 compared to the iPhone 14, due to competition from Huawei. Another report suggested that Goldman Sachs may withdraw from its consumer finance partnership with Apple, which could impact Apple's ambitions in the consumer finance sector.

Portfolio Pulse from Shanthi Rexaline

October 16, 2023 | 12:05 pm

EDIT

The FDA has granted Regenerative Medicine Advanced Therapy Designation to Editas Medicine's EDIT-301, a gene editing medicine, for severe sickle cell disease.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 12:04 pm

RNAZ

Transcode Therapeutics has reported successful treatment of preclinical melanoma tumors using its immunotherapy candidate, TTX-RIGA. The study showed a significant inhibition of tumor growth.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 12:02 pm

AMAM

Ambrx Biopharma has announced that two abstracts detailing updated safety and efficacy data from the ongoing Phase 1/2 trial, APEX-01 of ARX517 for metastatic castration-resistant prostate cancer were made available at the European Society of Medical Oncology.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 12:00 pm